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Decreased hippocampal translocator protein (18kDa)
expression in alcohol dependence: a [11C]PBR28 PET study
NJ Kalk1, Q Guo2,3, D Owen4, R Cherian5, D Erritzoe3, A Gilmour6, AS Ribeiro3, J McGonigle3, A Waldman4, P Matthews4, J Cavanagh7,
I McInnes6, K Dar8, R Gunn9, EA Rabiner9 and AR Lingford-Hughes3
Repeated withdrawal from alcohol is clinically associated with progressive cognitive impairment. Microglial activation occurring
during pre-clinical models of alcohol withdrawal is associated with learning deficits. We investigated whether there was microglial
activation in recently detoxified alcohol-dependent patients (ADP), using [11C]PBR28 positron emission tomography (PET), selective
for the 18kDa translocator protein (TSPO) highly expressed in activated microglia and astrocytes. We investigated the relationship
between microglial activation and cognitive performance. Twenty healthy control (HC) subjects (45 ± 13; M:F 14:6) and nine ADP
(45 ± 6, M:F 9:0) were evaluated. Dynamic PET data were acquired for 90 min following an injection of 331 ± 15 MBq [11C]PBR28.
Regional volumes of distribution (VT) for regions of interest (ROIs) identified a priori were estimated using a two-tissue
compartmental model with metabolite-corrected arterial plasma input function. ADP had an ~ 20% lower [11C]PBR28 VT, in the
hippocampus (F(1,24) 5.694; P= 0.025), but no difference in VT in other ROIs. Hippocampal [
11C]PBR28 VT was positively correlated
with verbal memory performance in a combined group of HC and ADP (r= 0.720, Po0.001), an effect seen in HC alone (r= 0.738;
P= 0.001) but not in ADP. We did not find evidence for increased microglial activation in ADP, as seen pre-clinically. Instead, our
findings suggest lower glial density or an altered activation state with lower TSPO expression. The correlation between verbal
memory and [11C]PBR28 VT, raises the possibility that abnormalities of glial function may contribute to cognitive impairment in ADP.
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INTRODUCTION
Alcohol dependence can lead to cognitive impairment. Severe
forms of alcohol-related brain damage are well recognized, but less
often acknowledged is that even apparently functioning alcohol-
dependent patients (ADPs) suffer from a range of cognitive
deficits.1,2 These include problems with memory and executive
function that persists for months.2 Though there is improvement
after one year of abstinence, these deficits affect the ability of
patients to engage with after-care and to remain abstinent.3–6
Multiple causal factors contribute to alcohol-related brain
damage including nutritional deficiencies, head injury and
cirrhosis (reviewed in ref. 7), but cognitive impairment in this
population can also occur in their absence.1 The mechanisms
responsible for this cognitive impairment are not understood.
Preventative interventions are limited to thiamine supplementa-
tion and relapse prevention. Each medicated detoxification is
associated with progressively worsening withdrawal symptoms
and progressive cognitive impairment.8,9 Detoxification is thus
both a cause for clinical concern, and an important opportunity for
intervention.
Microglia are specialized cells of macrophage lineage, highly
responsive to their local environment.10 They become ‘activated’,
a histological term describing the retraction of ramifications and
assumption of an amoeboid shape, in response to many stimuli,
including tissue damage. In the healthy brain, the microglial
activation is modulated by neurons11 and basal microglial
activation varies regionally. Microglia in the hippocampus express
genes that suggest pro-inflammatory priming, even in the
absence of disease.12
Several functional states of activation are recognized, and two
specifically named: an ‘M1’ neurotoxic phenotype that produces
pro-inflammatory cytokines, reactive oxygen species13 and
excitotoxins;14 and a neurotrophic ‘M2’ phenotype which secretes
anti-inflammatory cytokines, nerve growth factors and clears
debris via phagocytosis.15 It is hypothesized that further functional
types of activated microglia exist16 and that the type of activation
is contingent both upon the microenvironment,15 neuronal
regulation17 and systemic inflammation.18 Either overactivity of
the M1 phenotype or suppression of the M2 phenotype could be
associated with exacerbation of an acute or chronic neural insult.
Pre-clinical models of alcohol dependence demonstrate micro-
glial activation and expression of inflammatory mediators such as
tumor necrosis factor-α (TNFα) and interleukin-6 (IL-6) both in the
brain and peripheral blood during alcohol withdrawal.19,20 These
changes are associated with neuronal death and learning deficits.19
There is evidence that similar processes may occur in humans. An
increased density of microglia and increased expression of CCL2,
an inflammatory chemokine, are found in the anterior cingulate
cortex, midbrain and amygdala of ADPs postmortem.21 Pro-
inflammatory cytokines including IL-6 and IL-10 are elevated in
plasma (reviewed in ref. 22) and increased CCL2 is found in the
cerebrospinal fluid23 in ADP during withdrawal.
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Pre-clinically, hippocampal and piriform cortical microglial
activation and proliferation are found during alcohol
withdrawal19,24,25 and can persist for up to 3 weeks.19,26 Microglial
activation also is found in the cerebral cortex and cerebellum with
chronic alcohol administration in pre-clinical models, and further
increased after withdrawal.24
Glial cells, including microglia, can be detected in vivo in
humans using positron emission tomography (PET) radioligands
binding to the 18 kDa mitochondrial translocator protein (TSPO),
which is highly expressed in activated glia. Although increased
TSPO expression is associated with histological cell changes
consistent with activation, it does not distinguish between
different activation functions, that is M1 or M2 activation. TSPO
is also expressed in other central nervous system cell types,
including activated astrocytes, endothelium and blood compo-
nents such as acute phase proteins.27–29 Increased TSPO expres-
sion has been demonstrated pre-clinically using [3H]PK11195
autoradiography in chronic alcohol intake24 and withdrawal
models.19,26 [11C]PK11195 binding was increased in a small clinical
cohort with hepatic encephalopathy,30 three members of which
had a history of alcohol dependence, though they were long
abstinent. Activated microglia may therefore represent a target for
intervention around the time of alcohol withdrawal.
The aim of this study was therefore to investigate whether
increased TSPO radioligand binding suggesting microglial activa-
tion is found in ADP who had recently undergone medically
assisted withdrawal. A secondary objective was to explore the
relationship between this measure of microglial activation and
cognitive function. We hypothesized that increased [11C]PBR28
PET signal (measure as a volume of distribution, VT), would be
increased in the brains of ADP particularly in those regions
associated with microglial activation in pre-clinical or postmortem
samples (cerebellum, hippocampus, midbrain, thalamus and
cingulate cortex).19,21,24,31 Given that microglial activation has
been associated with neuronal damage in pre-clinical models of
alcohol withdrawal,19 we hypothesized that there would be a
negative correlation between TSPO expression and performance
on tests of verbal and spatial memory and executive function,
which are impaired in alcohol dependence.1
MATERIALS AND METHODS
ADP (DSM-IV) within 1 month of medically assisted withdrawal were
recruited through local addiction services, healthy control participants (HC)
via local volunteer databases, and HC data obtained from an concurrent
study running on the same scanner.32 Newly abstinent ADP rather than
actively drinking ADP were chosen for inclusion for several reasons. First,
the pre-clinical literature predominantly reported increased TSPO expres-
sion or microglial activation during and after alcohol withdrawal. Second,
scanning actively drinking ADP of the severity encountered in local clinical
services is technically challenging, as alcohol intoxication affects PET tracer
delivery and the patients are likely to enter withdrawal during scanning,
causing tremor, and potentially vomiting and seizures. We scanned people
following completion of withdrawal when they were no longer tremulous,
no longer taking benzodiazepines and able to tolerate study procedures.
Most ADP had undergone medically assisted detoxification with
chlordiazepoxide (n= 7) or diazepam (n= 1) before the study. Although
none were still taking benzodiazepines at the time of scanning (mean
duration since last dose 14 days (range 6–29 days)), three had a positive
urine screen for benzodiazepines, reflecting the long metabolite half-life.
As metabolites of chlordiazepoxide and diazepam do not bind the TSPO,
this was not a concern.33 All were prescribed thiamine and vitamin B
complex tablets, three acamprosate and one disulfiram.
Exclusion criteria applying to both groups included major physical or
psychiatric illness as assessed by the Mini-International Psychiatric
Interview (MINI-6),34 apart from a history of depression or anxiety, alanine
transaminase exceeding five times the upper limit of the normal range,
abnormal clotting parameters and consumption of steroids or non-
steroidal anti-inflammatory medication. All volunteers were tested for
rs6971 TSPO genotype, as the non-synonymous polymorphism at this site
leading to a single alanine to threonine substitution affects affinity of [11C]
PBR28 for TSPO.35 Heterozygote ‘Mixed Affinity Binders’ (MABs) have an
approximately 50% reduction in the binding relative to the ala:ala
homozygotes (‘High Affinity Binders’, HABs)36 while threo:threo homo-
zygote ‘Low Affinity Binders’ (LABs) have no detectable signal,37 so need to
be excluded. In this study, both HABs and MABs were scanned. All the
participants were required to produce a negative alcohol breath test on
the day of the scan and the alcohol-dependent group to score less than 10
on the Clinical Assessment of Withdrawal from Alcohol scale.38 Depen-
dence on other drugs, apart from tobacco, was an exclusion criterion for
both groups, but recreational use was allowed in ADP. All the participants
gave informed consent about data sharing and both studies received
approval from local NHS Research Ethics Committees and ARSAC.
Total lifetime alcohol consumption was assessed in both the groups by
the modified Skinner’s questionnaire.39 Physiological dependence in ADP
was quantified using the Severity of Alcohol Dependence Questionnaire.
All the participants completed the Spielberger Trait Anxiety Score,
Spielberger State Anxiety Score, Beck Depression Inventory and the
Fatigue Severity Scale.40–42 Those controls enrolled in the study
investigating alcohol dependence also completed the Obsessive Compul-
sive Drinking Scale.43 Cognitive tests were completed on the day of
scanning from a battery previously used by us1 including digit span, Trail
Making Task A and B,44 the Rey-Osterrieth Figure (ROCF)45 and Weschler
Memory Scale paragraph version (WMS).46
Plasma samples were taken at the start of the PET scan in the ADP group
for the analysis of diazepam, chlordiazepoxide and their common
metabolite desmethyldiazepam, using high-performance liquid chromato-
graphy (threshold44 μg ml− 1) as the ADP group were recently prescribed
benzodiazepines and some tested positive for benzodiazepines on urine
drug screen. No controls tested positive for benzodiazepines. The serum
samples were analysed in the University of Glasgow for 25 cytokines and
chemokines via Luminex human multiplex. High-sensitivity C-reactive
protein (0.3–500 mg dl− 1) was analysed by clinical biochemistry services at
the Hammersmith Hospital, London, UK.
The participants were scanned as described previously.32 Briefly, each
participant received a 90 min [11C]PBR28 PET scan following a bolus
injection of [11C]PBR28 (HC: mean 330.4 MBq, range: 312.4–347.3 MBq;
ADP: mean 328.9 MBq, range: 302.7–346.5 MBq), after which dynamic
three-dimensional PET data were acquired over 90 min. Continuous arterial
blood samples were collected every second from the radial artery for the
first 15 min. Discrete blood samples were manually withdrawn at 5, 10, 15,
20, 25, 30, 40, 50, 60, 70, 80 and 90 min after scan start to facilitate
measurement of whole-blood and plasma activity. The participants also
received a high-resolution T1-weighted magnetic resonance imaging (MRI)
scan in a Siemens Verio 3T scanner (Siemens Healthcare, Erlangen,
Germany). A consultant neuroradiologist reviewed each MRI scan. Any
subjects with clinically significant structural lesions were excluded from the
analysis.
The PET images were reconstructed via filtered back projection with
attenuation and scatter correction. Dynamic images were separated into
26 frames (8 × 15 s, 3 × 1 min, 5 × 2 min, 5 × 5 min, 5 × 10 min). A
metabolite-corrected plasma input function was generated using a
method described previously.32 The total plasma time activity curve was
calculated by multiplying the whole-blood curve by plasma-over-blood
ratio, and the parent fraction data were fitted to a sigmoid model:
f ¼ 1 - t
3
t3 þ 10a
 b
þ c
 !
= 1þ cð Þ
where t is time and a, b and c are fitted parameters. The fitted parent
fraction profile was multiplied by the total plasma curve and then
smoothed post-peak using a tri-exponential fit to derive the required
parent plasma input function. A time delay correction was applied to
account for delays between blood sample measurement and tomographic
tissue measurement.
For analysis, we used the PET data analysis and kinetic modelling toolkit,
MIAKAT (www.miakat.org),47 which also uses software from SPM5 (Well-
come Trust Centre for Neuroimaging) and FSL (FMRIB, University of
Oxford). The PET data were corrected for motion via frame-by-frame co-
registration to each participant’s T1 MRI. Anatomical ROIs were delineated
by the application of the CIC neuroanatomical atlas,48 warped to the
participant’s structural MRI scan. The ROIs were applied to the PET data to
derive regional time activity curves.
We used a two-tissue compartmental model using a metabolite-
corrected input function, with blood volume fixed at 5%, applied to
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dynamic PET data as described.49 Volume of distribution (VT) was
estimated according to the following equation:
VT ¼ K1=k2 1þ k3k4
 
where VT is the regional volume of distribution, K1 and k2 are rate constants
for the movement of [11C]PBR28 from plasma to brain parenchyma and
parenchyma to plasma respectively, and k3 and k4 are rate constants for
the movement of [11C]PBR28 from the nondisplaceable ligand in the tissue
to bound to the specific target, and from bound to nondisplaceable,
respectively. As several of the volumes of interest specified a priori—
hippocampus, midbrain, thalamus—were relatively small volumes adjacent
to cerebrospinal fluid, partial volume correction using LoReAN, a hybrid
voxel-region-based algorithm,50 was undertaken.
Participants’ structural MRI scans were compared using voxel-based
morphometry to establish whether there were volumetric differences in
ROIs between groups. Following segmentation, segmented tissue maps of
each subject were registered to their common average using DARTEL,51
then affine registered to the MNI space. The warped images were
modulated with the Jacobian determinants of the deformations52 and
smoothed with an isotropic Gaussian kernel with a full width at half
maximum of 8 mm.
The sample size was informed by biomathematical modelling, because
of the relative novelty of the tracer and uncertainty about the anticipated
diference between groups.53 Demographic differences between groups
were assessed using unpaired two-tailed t-tests applied to parametric data,
and Mann–Whitney tests to non-parametric data. Analyses of covariance,
implemented in SPSS 20.0 were performed to examine the effect of patient
group on [11C]PBR28 VT across ROIs identified a priori. Genotype was
included as a fixed factor in the analysis as it is known to influence VT. Age
was included as a covariate as TSPO expression increases with age.54
Equality of variance was confirmed using Levene’s test. A two-way analysis
of variance was used to investigate whether there were differences in the
area under the curve of the input function or in free fraction between
groups. A post hoc analysis of VT in 20 brain regions defined by the CIC
atlas (including the frontal lobe, parietal lobe, temporal lobe, occipital lobe,
functional subdivisions of these relevant to addiction such as insula and
medial prefrontal cortex, thalamus, caudate, putamen, hippocampus,
midbrain, pons, medulla and cerebellum) using a mixed-effects model to
examine the effects of patient group, region and a patient group× region
interaction, corrected for age and genotype, was undertaken. Two-tailed
partial correlations, accounting for age and genotype, were performed
between hippocampal VT and performance on the WMS, ROCF and frontal
VT and performance on trail making tasks. The primary analysis combined
ADP and HC in one group, because of the small sample size. The groups
were considered separately in a secondary analysis. A mass univariate
general linear model was applied to compare relative grey matter volumes
between groups on a voxel-by-voxel basis, accounting for age and
intracranial volume, with family-wise error correction (Po0.05). Mann–
Whitney U-tests were used to examine the differences between groups in
circulating cytokine concentrations. In a secondary, exploratory analysis,
Spearman correlations were performed between individual cytokine
concentrations and TSPO binding.
RESULTS
Clinical characteristics
The clinical characteristics of the study sample are shown in
Table 1. There were no significant group differences in educational
attainment between ADP and HC. Most ADP had had at least one
previous detoxification (median 1 (range 0–7)) and were
moderately to severely dependent (Severity of Alcohol Depen-
dence Questionnaire: 29 ± 9). ADP scored higher on measures of
alcohol craving, depression and anxiety, and the Fatigue Severity
Scale. ADP performed less well on tests of verbal and spatial
memory, but there were no differences in performance on tests
related to executive function.
Mean high-sensitivity C-reactive protein was within normal
range in both the groups. Albumin was significantly lower in ADP
and GGT significantly higher, but other liver function tests were
within normal limits in both the groups (see Table 2). No diazepam
or chlordiazepoxide was detectable in any blood samples, but
desmethyldiazepam was detectable in three ADP (370 ± 148 nM).
There was no significant difference (P40.05) in concentrations of
any of the cytokines measured (see Table 2).
Table 1. Characteristics of the sample
Alcohol-dependent Control P
Demographic data
N 9 20
Age 45± 13 45± 7 0.590
Male:female 9:0 14:5
TSPO genotype (HABs:MABs) 3:6 10:10
Lifetime dose (kg) 83.29 (14.57–273.96) 10.91 (0–39.92) 0.005**
Alcohol use over past 28 days/28 days before detoxification (g) 5616 (1680–10 080) 244 (0–1080) o0.001**
Current cigarette smoking (n) 8 5
Illicit drug use 4 0
Past history of depression 4 2
Severity of Alcohol Dependence Questionnaire 29± 9
Obsessive Compulsive Drinking Scale 12.4± 8.0 3.9± 2.4 0.003**
Beck Depression Inventory 11± 6 4± 4 0.002**
Spielberger Trait Anxiety Inventory 44± 6 35± 11 0.015*
Spielberger State Anxiety Inventory 33± 10 29± 9 0.013*
Fatigue Severity Scale 4± 0.7 2± 1.2 0.004**
Cognitive tests
Weschler Memory Scale Immediate 8± 2.9 11± 2.8 0.027*
Weschler Memory Scale Delayed 6± 2.5 9± 3.6 0.013*
Rey-Osterrieth Complex Figure Immediate 14± 11.2 20± 8.4 0.147
Rey-Osterrieth Complex Figure Delayed 14± 9 21± 7.9 0.048*
Trails A (time to complete) 30.3± 9.30 29.32± 16.9 0.861
Trails B (time to complete) 62.8± 36.48 57.7± 30.25 0.700
Digit span 16.0± 3.12 17.6± 4.52 0.340
Abbreviations: HAB, High Affinity Binders; MAB, Mixed Affinity Binders; TSPO, translocator protein. Parametrically distributed data are presented as mean± s.d.
Non-parametrically distributed data are presented as median (range). *Po0.05; **Po0.01. Illicit drug use in alcohol group: two participants used cocaine and
two used cannabis.
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Group differences in [11C]PBR28 VT
Hippocampal [11C]PBR28 VT (corrected for the effects of genotype
and age) was 19% lower in ADP relative to HC (F(1,24) 5.694;
P= 0.025; partial η2 = 0.192). Group mean time activity curves for
the hippocampus are shown in Figure 1, with HABs and MABs
shown separately. Mean VTs in the hippocampus for all genotypes
and groups are shown in Figure 2. Differences in other ROIs
identified a priori—midbrain, thalamus, cerebellum and anterior
cingulate cortex—did not reach statistical significance (midbrain:
P= 0.061, partial η2 = 0.139; thalamus: P= 0.091, partial η2 = 0.115;
cerebellum P= 0.100, partial η2 = 0.108 and anterior cingulate
cortex: P= 0.078, partial η2 = 0.124; see Figure 3). The mixed-
methods analysis undertaken to interrogate whether there was a
general effect of patient group or an interaction between patient
group and region, corrected for age and genotype, found no
significant effect of patient group (F = 1.736; P= 0.200), but a
significant effect of region (F = 10.610; Po0.001) and a significant
region ×patient group interaction (F = 2.294; P= 0.002). There
were no differences in the area under the curve of the input
function between the groups (HAB HC: 2219 ± 334.6; HAB ADP:
2523.8 ± 686.8; MAB HC: 2436 ± 551.9; MAB ADP: 2475 ± 928.5;
P= 0.566) or in free fraction (HAB HC: 0.0247 ± 0.0161; HAB ADP:
0.0115 ± 0.0046; MAB HC: 0.0176 ± 0.0115; MAB ADP:
0.0191 ± 0.0054, P= 0.424).
Exploratory correlates of [11C]PBR28 VT
There were no significant correlations between peripheral
cytokine concentrations and [11C]PBR28 VT. Age and genotype
were significantly associated with variation in [11C]PBR28 VT in all
Table 2. Blood results in ADP and HC
Alcohol-dependent Control P
Standard clinical blood tests
Haemoglobin 14.8± 1.2 14.6± 1.2 0.731
Mean cell volume 96.1± 6.1 84.9± 13.6 0.007**
White cell count 9.3± 2.0 6.5± 1.3 0.002**
Bilirubin 8± 5 12± 8 0.161
Alanine transaminase 56± 20 26± 8 0.110
Alkaline phosphatase 71± 50 68± 19 0.702
Gamma glutamyl transferase 134 (range 15–466) 30± 20 0.064
Albumin 40± 3 44± 3 0.004**
Adjusted partial thromboplastin time 26.6± 2.3 28± 2 0.086
C-reactive protein 3.0± 2.39 2.6± 3.63 0.775
Pro- and anti-inflammatory cytokines
Tumour-necrosis factor α 0 (0–225.29) 0 (0–859.03) 0.776
Interleukin 1β 0 (0–414.77) 0 (0–1288.16) 0.776
Interleukin 1 receptor antibody 0 (0–518.83) 0 (0–1696.38) 0.776
Interleukin 6 0 (0–285.06) 0 (0–902.75) 0.882
Interleukin 10 130.31 (60.68–537.95) 74.00 (42.50–1283.45) 0.412
GM-CSF 61.64 (26.99–387.18) 41.69 (11.77–1173.56) 0.370
Type 1 interferons
Interferon α 0 (0–305.73) 0 (0–902.75) 0.824
Cytokines related to T-cell activation
IL-2 0 (0–292.86) 0 (0–866.97) 0.710
IL-7 32.89 (23.84–64.53) 36.60 (17.88–359.04) 0.552
IL-15 0 (0–916.53) 0 (0–2933.43) 0.766
IL-2R 21.87 (2.28–227.93) 12.15 (4.84–595.21) 1.000
Th1 cytokines
IL-12 10 019 (4770–46 685) 10 205 (8258–29 077) 0.412
IFN-γ 0 (0–225.29) 0 (0–859.03) 0.766
Th2 cytokines
IL-5 5.06 (3.51–560.75) 5.93 (3.1–1667.44) 1.000
IL-13 39.53 (0–1357.48) 26.59 (0–4083.75) 0.766
Th17 cytokines
IL-17 22.89 (15.64–663.44) 19.39 (15.64–2174.24) 0.552
Chemokines
CXCL-8 (IL-8) 20.16 (10.68–1439.79) 11.6 (2.91–2808.70) 0.131
CXCL-9 (MIG) 0 (0–1698.11) 0 (0–5066.90) 0.766
CXCL-10 (IP-10) 170.46 (60.82–1088.97) 82.56 (0–3133.54) 0.131
CCL-2 (MCP-1) 0 (0–196.47) 0 (0–663.28) 0.710
CCL-3 (MIP-1α) 0.29 (0.19–595.03) 0.29 (0.19–2204.86) 0.824
CCL-4 (MIP-1β) 855.78 (218.01–2023.38) 399.59 (160.48–3672.07) 0.201
CCL-5 (RANTES) 189.59 (48.06–637.74) 105.53 (45.23–609.39) 0.295
CCL-11 (Eotaxin) 19.39 (10.56–839.90) 22.11 (7.41–2334.10) 0.656
Abbreviations: ADP, alcohol-dependent patients; GM-CSF, gray matter-cerebrospinal fluid; HC, healthy controls; IFN, interferon; IL, interleukin. For
parametrically distributed data, mean± s.d. is displayed. For non-parametrically distributed data, median (range) is displayed. **Po0.01.
Microglial activation and cognitive performance
NJ Kalk et al
4
Translational Psychiatry (2017), 1 – 8
the brain regions tested (for example, in the hippocampus:
genotype F(1,24) = 8.190; P= 0.009; age: F(1,24) = 5.370; P= 0.029).
There was no patient group ×genotype interaction (P40.05). VT
was not associated with duration of abstinence in alcohol-
dependent group in any ROI. Voxel-based morphometry con-
ducted using the MRI structural images to establish whether there
was atrophy in ADP revealed no significant differences between
the groups (family-wise error corrected P40.05; t-statistic thresh-
old = 6.01). The peak t-statistics for the ROIs identified a priori were
as follows: anterior cingulate cortex: 1.805; left hippocampus
1.680; right hippocampus: 1.447; midbrain 2.885; left thalamus:
2.031; right thalamus: 2.840; cerebellum: 2.312.
Hippocampal [11C]PBR28 VT and cognitive performance measures
There was a positive correlation (after controlling for the effects of
age and genotype) between hippocampal VT and both WMS and
ROCF performance (WMS: r= 0.720, Po0.001; ROCF: r= 0.541;
P= 0.004; see Figure 4) when ADP and HC were combined in one
group. A positive correlation was also found in the HC group alone
between hippocampal VT and scores on the delayed WMS
(r= 0.738; Po0.001),46 but not scores on the delayed ROCF
test45 (r= 0.445; P= 0.073). The ADP clustered at the lower end of
Figure 1. Time activity curves in the hippocampus. This figure shows mean time activity curves with error bars representing standard
deviation, from the hippocampus in healthy controls, shown in black, and alcohol-dependent patients (ADPs), shown in red. HAB, high-affinity
binder; MAB, mixed-affinity binder; SUV, standardized uptake value.
Figure 2. [11C]PBR28 VT is lower in the hippocampi of alcohol-
dependent patients (ADPs) than in controls (mean± s.d.). This figure
shows VT of individual participants grouped by genotype with ADPs
shown as red squares and healthy controls (HCs) as blue circles. The
bars show mean and standard deviation in each group. HAB, high-
affinity binder; MAB, mixed-affinity binder.
Figure 3. Lower VT in regions of interest (ROIs) apart from the
hippocampus did not reach significance (mean+s.d.). This figure
shows mean VT and standard deviation in all the ROIs identified a
priori. Healthy controls (HCs) are blue and alcohol-dependent
patients (ADPs) are red. The bars reflect both patient group and
genotype. ACC, anterior cingulate cortex; HAB, high-affinity binder;
MAB, mixed-affinity binder.
Figure 4. Correlation between hippocampal VT and verbal memory.
This figure shows the positive relationship between hippocampal
binding and performance on a verbal memory task. Healthy controls
(HCs) are blue and alcohol-dependent patients (ADPs) are red. Filled
squares/dots are HABs and unfilled squares/dots are MABs. HAB,
high-affinity binder; MAB, mixed-affinity binder.
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the distribution of HC in the combined analysis but the correlation
with verbal memory was not significant in the ADP group alone
(r= 0.331; P= 0.468). There were no associations between hippo-
campal VT, and performance on digit span or the trail making task,
nor any associations between the frontal cortex VT and
performance on digit span or the trail making task.
DISCUSSION
To the best of our knowledge, this is the first study to report
changes in [11C]PBR28 VT in a cohort of otherwise healthy ADPs
within the first few weeks of abstinence. Refuting our initial
hypothesis, we found that [11C]PBR28 VT is decreased in the
hippocampus in recently abstinent ADPs relative to healthy
participants with no significant changes in other brain ROIs
identified a priori. In an exploratory analysis, we also found a
positive relationship between hippocampal [11C]PBR28 VT and
verbal memory in the healthy participants. When the patient and
healthy control group were combined, the correlation remained
and a significant positive correlation was found between
hippocampal [11C]PBR28 VT and both verbal and spatial memory.
We hypothesized that [11C]PBR28 binding would be increased
in alcohol withdrawal, based on pre-clinical evidence.19,20,25,26
However, our findings of a decrease are more consistent with
either a decrease in expression of the protein or a loss of cells
expressing the protein. TSPO is a mitochondrial protein and would
therefore be expected to decrease with a reduction of mitochon-
drial density. Slight decreases in mitochondrial enzymes and
uncoupling with production of potentially damaging free radicals
have been reported in a pre-clinical chronic alcohol model.55
Alternatively, decreases in the activation state, or absolute
numbers of several populations of cells could explain the
reduction seen. First, loss, or altered activation, of microglia or
astrocytes could explain the change. The one existing stereo-
logical human postmortem study of microglia and astrocytes in
ADP, which included data on the hippocampus supports this as
there was selective loss of both astrocytes and microglia.56 Prior
human magnetic resonance spectroscopic results showed no
decreases in myo-inositol, a metabolic marker for activated
astrocytes, in recently abstinent alcoholics57,58 making astrocytic
changes around the time of withdrawal less likely than microglial
changes. Pre-clinically, microglial activation during alcohol with-
drawal has been reported to be M2 activation, raising the
possibility that loss of such activation may hamper repair.26
Second, lower [11C]PBR28 binding could relate to suppressed
neurogenesis, as TSPO is also expressed by hippocampal neural
stem cells.59 Pre-clinical findings regarding the effect of alcohol on
neurogenesis have yet to be replicated in human postmortem
samples, which showed no differences in numbers of neural
progenitors between ADP and HC in the subventricular zone and
olfactory bulb.60 Absolute numbers of neural progenitors are low
in adult humans, making this unlikely.60 Finally, TSPO is also
expressed in the endothelial cells,61 so microvascular changes
could contribute to our findings. Changes in the hippocampal
capillary lumen diameter and decrease in the length and density
has been described in at least one pre-clinical chronic alcohol
model.62
The difference between pre-clinical findings and the outcome
of this clinical study may relate to differences between pre-clinical
models of alcohol dependence and clinical populations. Pre-
clinical studies are performed in adolescent rodents, and periods
of heavy alcohol exposure are relatively short (o2 weeks). For
logistical reasons, we were not able to scan patients during the
first week of withdrawal. Some pre-clinical models show only very
short-lived microglial activation,26,63 but others show activation at
3 weeks of abstinence.19 There was no relationship between
duration of abstinence and [11C]PBR28 VT in our study, though
it was not designed to investigate this. Of interest is that while
pre-clinical studies in cocaine dependence have reported pro-
inflammatory gene expression,64 clinical imaging has shown no
difference in TSPO expression,65 suggesting there may be similar
translational challenges across addictions.
Clinical populations in the United Kingdom are medicated with
benzodiazepines during withdrawal. Suppression of microglial
activation via GABA(A) transmission has been reported raising
the possibility that microglial suppression by benzodiazepines
explains the decrease.66 A direct effect of benzodiazepines
binding the TSPO is however unlikely as only diazepam at high
dose binds the TSPO and the only benzodiazepine present in the
ADP plasma was the metabolite desmethyldiazepam, which does
not bind the TSPO.33
We found that hippocampal [11C]PBR28 binding was positively
associated with verbal memory in the sample considered as a
whole and in healthy controls. Although ADPs clustered towards
the lower end of the distribution, the relationship was not
maintained in ADPs alone—probably because of small numbers,
particularly small numbers of HABs, who have a higher signal-to-
noise ratio. To detect a correlation of the strength of that seen in
HC with 80% power, 11 HABs would have been needed.
The positive correlation between TSPO expression and memory
could be attributed to the function of the protein itself or the cells
which express it. TSPO over-expression has been found pre-
clinically to protect against lipopolysaccharide induced memory
dysfunction.67 The relationship between mitochondrial function,
TSPO expression and memory function under healthy conditions
has not been explored. Microglia and astrocytes are both involved
in memory function in the healthy hippocampus: while microglia
integrate neural progenitors into hippocampal circuits and
undertake activity-related synaptic remodelling (reviewed in ref.
68), astrocytic release glutamate, adenosine triphosphate and
cytokines helps to consolidate nascent synaptic connections.69
The positive correlation seen in healthy participants supports the
importance of microglia and astrocytes, and perhaps TSPO itself,
in the healthy functioning of the hippocampus.
Although we did not find a correlation in the ADPs alone, the
finding of a positive relationship between memory performance
and TSPO expression is intriguing. Verbal and spatial memory
deficits, which relate to hippocampal function, are well described
in alcohol dependence.1,70,71 We did not find brain volume
changes in our small ADP sample, but larger volumetric studies
have shown hippocampal atrophy in alcohol-dependent
cohorts.72–75 No relationship between volume loss and memory
has been demonstrated, raising the possibility that loss or
dysfunction of cell subsets such as microglia or astrocytes is a
more important determinant.
The moderately to severely dependent drinkers that we studied
were challenging to recruit and retain as they were relatively
unstable and at high risk of disengagement from treatment.
Recruitment challenges affected both statistical power to detect
the group differences and stringency of inclusion and exclusion
criteria. The study is therefore affected by limitations mainly
around size and design. Our patient sample is small, was scanned
on average 3 weeks from cessation of alcohol, were receiving
relapse prevention medications and were more likely to be
smokers. The small sample meant we were unable to interrogate
the possible contribution of these factors. Another limitation is
that the majority of the patient group had undergone medicated
detoxification, raising the possibility that changes are seen related
to medications taken during detoxification or other non-specific
effects.
We found a statistically significant decrease in [11C]PBR28 VT in
the hippocampus of ADPs shortly following alcohol withdrawal
consistent with microglial or astrocytic loss or functional change,
or changes in TSPO expression related to oxidative stress or
mitochondrial pathology. This finding is supported by a previous
postmortem study showing hippocampal microglial and astrocytic
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loss in ADP. Hippocampal [11C]PBR28 VT indicative of TSPO expres-
sion was positively correlated with performance on a delayed
memory task, suggesting this may be of clinical relevance. This
relates to pre-clinical research suggesting that microglial activa-
tion may be related to homeostatic functions rather than
inflammatory functions in the hippocampus under healthy
conditions. Binding was not higher in the alcohol-dependent
participants, raising questions about microglial and mitochondrial
function in this context and how this may translate into treatment
targets. It remains to be established whether an increase in TSPO
expression occurs in humans during chronic drinking, or in binge
alcohol exposure, which more closely resembles animal models.
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